Launch Preview at 19th EU‑China Business Meeting

LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd., a tenant of Tianfu International Bio City, presented the global launch preview of its core product POGMENT® Triple‑Helix Biomimetic Collagen‑Based Extracellular Matrix (ECM) medical devices on 24 October 2026 in Chengdu, China, during the 19th EU‑China Business Meeting co‑hosted by the China Chamber of International Commerce (CCOIC) and the European Union Chamber of Commerce in China (EUCCC).

Market Reception

The company’s booth recorded 55 European visitors, of which 29 were classified as high‑intent prospects. Attendees from Switzerland, Spain, France and other countries tested the SMARTENDER® Triple‑Helix Biomimetic Collagen series, noting superior transdermal absorption and relief of persistent skin dehydration. Pablo, Executive Director of the China‑Spain Chamber of Commerce, commented positively on the skin‑feel after using the face mask.

Strategic Outlook

Founder Dr. Qin Xingjiong articulated a “born‑global” strategy, stating that securing the European market would serve as a passport to the United States, Japan, South Korea and Southeast Asia, given Europe’s stringent regulatory science system. The company seeks comprehensive cooperation covering trade, certification, ODM joint manufacturing, product development, scenario expansion and secondary technology development.

Technical Innovation

LivingPHOENIX’s world‑first triple‑helix biomimetic collagen ECM is produced via green biomanufacturing of amino acids, aqueous‑phase chemical condensation, and engineered assembly, delivering a material that tolerates 121 °C terminal sterilisation, doubles mechanical strength and enhances biological functionality compared with second‑generation recombinant collagen. The product matrix spans Class II medical devices, cosmetics, Class III aesthetic devices and implantable Class III devices. The launch preview includes eight Class II dressing products – sterile patches, liquid dressings, repair dressings, scar gels and gynecological gels – benchmarked against leading international cosmetics‑medical device integrations.

Regulatory Timeline

The National Medical Products Administration (NMPA) is expected to grant approval between November and December 2026. The first product has completed system assessment and is undergoing supplementary information requests and corrective actions.

Intellectual Property

Two core invention patents covering triple‑helix biomimetic collagen self‑crosslinking hydrogels and ECM regenerative materials have passed preliminary examination in Chengdu and entered substantive review at the China National Intellectual Property Administration (CNIPA). To date, LivingPHOENIX has filed 14 invention patents (8 Chinese, 6 PCT), with four core patents granted and registered as patent‑intensive products. The firm is pursuing Patent Prosecution Highway (PPH) routes for the United States, South Korea and Europe.

Commercial Validation

The SMARTENDER® functional skincare brand, built on the same technology, launched in November 2025 and has been validated by 25,000 real‑user tests and high influencer repurchase rates, confirming safety, efficacy and user retention.

Research and Partnerships

LivingPHOENIX collaborates with domestic universities on a National Natural Science Foundation major project titled “Biomimetic Collagen Gels” and conducts pre‑clinical studies with Beijing Hospital, Peking University Third Hospital and Shanghai Ninth People’s Hospital. Findings have been published in SCI‑Q1 journals such as Frontiers in Bioengineering and Biotechnology.

Awards and Recognitions

The POGMENT® project has earned multiple accolades: Champion of the Startup Group in the 13th Provincial Innovation Competition, Third Place in the Growth Group of the 15th Provincial Competition, advancement to the national semi‑finals of the MIIT Bio‑Manufacturing Competition (Application Innovation Track), top‑ten placement in MIIT’s “Maker China” Innovation Competition (Medical Health Special Track), and finalist status in the Golden Panda Global Innovation and Entrepreneurship Competition, among others.

Future Expansion

The underlying technology is being extended to high‑value medical consumables such as cartilage repair scaffolds, bone repair materials and cardiovascular patches, positioning the company as a core force in regenerative medicine.

Closing Statement

Dr. Qin emphasized that LivingPHOENIX is not merely producing a material but establishing a replicable Chinese standard for regenerative material technology, aiming for rapid commercialization while maintaining compliance.